CSIMarket Company Name, Ticker, Suppliers, else..
 
Fortress Biotech Inc   (NASDAQ: FBIO)
 
Price: $2.7200 $0.01 0.369%
Day's High: $2.740000009536743 Week Perf: -0.73 %
Day's Low: $ 2.67 30 Day Perf: -1.81 %
Volume (M): 168,115 52 Wk High: $ 4.53
Volume (M$): $ 0 52 Wk Avg: $3.01
Open: $2.68 52 Wk Low: $2.18



 Market Capitalization (Millions $) 86
 Shares Outstanding (Millions) 32
 Employees 78
 Revenues (TTM) (Millions $) 70
 Net Income (TTM) (Millions $) 158
 Cash Flow (TTM) (Millions $) 181
 Capital Exp. (TTM) (Millions $) 0

Business Description


Fortress Biotech Inc is a biopharmaceutical company based in the United States that focuses on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. The company operates through multiple subsidiary companies, each specializing in a different therapeutic area such as oncology, rare diseases, and gene therapy. Fortress Biotech's unique model allows it to leverage the expertise of its subsidiary companies while providing them with the necessary resources for research, development, and commercialization. By partnering with leading academic institutions and strategic partners, Fortress Biotech aims to bring novel and promising therapies to patients in need.


   Company Address: 1111 Kane Concourse Suite 301 Bay Harbor Islands 33154 FL
   Company Phone Number: 652-4500   Stock Exchange / Ticker: NASDAQ FBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        2.68% 
MRK        1.33% 
OGN        0.15% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Merger and Acquisition

Fortress Biotech Seals Deal for Checkpoint Therapeutics: A $28 Million Boost and Promising Future Royalties!,

Published Fri, May 30 2025 2:48 PM UTC

Fortress Biotech Clinches Significant Deal with Checkpoint Therapeutics: $28 Million Incoming and Future Royalties AheadIn a landmark move, Fortress Biotech has announced the closing of its agreement to sell its subsidiary, Checkpoint Therapeutics, a transaction that stands to bolster its financial landscape significantly. The sale is set to provide Fortress with approximat...
Financing Agreement

Fortress Biotech Strengthens Its Position with $8 Million Registered Direct Offering and Private Placements, Ushering in a New Era of Innovation and Growth,

Published Fri, Sep 20 2024 12:31 PM UTC

Fortress Biotech Makes Strategic Move with $8 Million Registered Direct Offering to Support Growth and InnovationMIAMI, Sept. 20, 2024 Fortress Biotech, Inc. (Nasdaq: FBIO), a dynamic biopharmaceutical firm dedicated to acquiring and advancing innovative assets, has announced a significant financial maneuver designed to bolster its growth and enhance shareholder value. On...
Stock Market Announcement

Fortress Biotech: Paving the Way for Innovation and Growth in Biopharmaceuticals

Published Thu, Jul 25 2024 12:31 PM UTC

The economic potential of Fortress: Extending debt maturity in anticipation of regulatory approvals and future growth
Fortress Biotech, Inc. recently announced the extension of the maturity of its long-term debt, signaling confidence in their late-stage pipeline and the potential for significant regulatory approvals in the near future. With up to three approvals on New D...
Dividend

Fortress Biotech Inc Pauses Dividend Payments on Series A Preferred Stock, Shareholders Feel Impact

Published Fri, Jul 5 2024 8:05 PM UTC


In a recent press release, Fortress Biotech, Inc. announced that its Board of Directors has decided to pause the payment of dividends on the Company s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock until further notice. This decision has raised concerns among shareholders, as dividends on the Series A Preferred Stock will continue to accrue and cumulate...
Clinical Study

Triplex: A Promising Breakthrough in CMV Control for Liver Transplant Patients

Published Tue, May 14 2024 12:31 PM UTC

Cytomegalovirus (CMV) is a significant concern in patients undergoing liver transplantation, as it poses a serious threat to both graft and patient survival. In light of this challenge, Fortress Biotech s majority-owned subsidiary, Helocyte, has commenced a groundbreaking Phase 2 study utilizing Triplex, a novel preventive and therapeutic approach for the effective managemen...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.68
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.24
Price to Sales (Expected) -
Price to Book 0.42
PEG (TTM) 0.01

Financial Strength Current
Quick Ratio 1.81
Working Capital Ratio 2.25
Leverage Ratio (MRQ) 0.97
Total Debt to Equity 0.2
Interest Coverage (TTM) -
Debt Coverage (TTM) 3.85

Per Share Current
Earnings (TTM) 4.02 $
Revenues (TTM) 2.2 $
Cash Flow (TTM) 5.71 $
Cash 6.18 $
Book Value 6.48 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 897,218
Net Income per Employee (TTM) 2,030,308
Receivable Turnover Ratio (TTM) 7.55
Inventory Turnover Ratio (TTM) 2.34
Asset Turnover Ratio (TTM) 0.27

Profitability Ratios Current
Gross Margin (MRQ) 67.18 %
Operating Margin (MRQ) -53.46 %
Net Margin (MRQ) 3.22 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 2.96 %

Management Effectiveness Current
Return On Assets (TTM) 60.76 %
Return On Investment (TTM) 72.39 %
Return On Equity (TTM) 118.22 %
Dividend Yield -
Pay out Ratio (TTM) 0.25 %



Fortress Biotech Inc's Segments
Journey    99.52 % of total Revenue
Fortress    0.48 % of total Revenue
Emrosi    38.98 % of total Revenue
Qbrexza    31.35 % of total Revenue
Accutane    20.66 % of total Revenue
Foam franchise products Amzeeq Zilxi    6.55 % of total Revenue
Other legacy product revenue    1.73 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.